Angiogenesis is essential to the process of neovascularization under both physiological and pathological conditions, including cancer, diabetic retinopathy, rheumatoid arthritis, and ischemia. Angiogenic markers are potential prognostic markers for disease activity and indicators of response to chemotherapy. Various strategies have been designed to target vascular endothelial growth factor receptor (Flt-1/VEGFR) signal transduction. Several VEGF-neutralizing antibodies have been successful in combination with chemotherapy in limiting angiogenesis and tumor progression. Other strategies to target the VEGF/Flt-1 pathway include soluble VEGFRs (Traps), receptor tyrosine-kinase inhibitors that target VEGFR2/Flk-1, and neutralizing aptamers.

MSD provides solutions to support and simplify your angiogenesis & vascular research needs. We offer singleplex and multiplex assays to measure biomarkers such as FGF (basic), FLT-1, Tie-2, and VEGF.

• Human
• Mouse
• Rat
• Canine
• Non-human primate
• All Species

Title	Journal	Year
Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma Frederick L.Locke, Sattva S. Neelapu, Nancy L.Bartlett, Tanya Siddiqi, Julio C.Chavez, Chitra M.Hosing, Armin Ghobadi, Lihua E.Budde, Adrian Bot, John M.Rossi, Yizhou Jiang, Allen X.Xue, Meg Elias, Jeff Aycock, Jeff Wiezorek, William Y.Go	Molecular Therapy	2017
Decrease of circulating SAA is correlated with reduction of abdominal SAA secretion during weight loss. Yang RZ, Blumenthal JB, Glynn NM, Lee MJ, Goldberg AP, Gong DW, Ryan AS.	Obesity	2013
Endothelial injury markers before and after nasal continuous positive airway pressure treatment for obstructive sleep apnoea hypopnoea syndrome. Wilczynska M, Rice S, Davies G, Lewis KE.	Sleep Breath	2013
Phase I study of Dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma. Angevin E, Lopez-Martin JA, Lin CC, Gschwend JE, Harzstark A, Castellano D, Soria JC, Sen P, Chang J, Shi M, Kay A, Escudier B.	Clin Cancer Res	2013
Phase II study evaluating 2 dosing schedules of oral Foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer. Shah MA, Wainberg ZA, Catenacci DVT, Hochster HS, Ford J, Kunz P, Lee F, Kallender H, Cecchi F, Rabe DC, Keer H, Martin A, Liu Y, Gagnon R, Bonate P, Liu L, Gilmer T, Bottaro DP.	PLoS One	2013
View All